Clinical evaluation of the effect on oral administration of tarÄ? mÄ?ttirai in management of Vitiligo

Clinical evaluation of the effect on oral administration of tarÄ? mÄ?ttirai in management of VENKUTTAM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/07/020042

Enrollment

Registered

2019-07-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: tarÄ? mÄ?ttirai: The test drug will be administered orally and externally. internal dose - thettrankottai alavu(Strycnus potatorum) 1/2 - 1 tablet two times a day with an adjuvant of su

Eligibility

Inclusion criteria

Inclusion criteria: The patient attending to the OPD will be screened for the following symptoms and will be included in the study Primary symptoms 1. Hypopigmented patches with hyperpigmented border without any structural changes in any part of the body surface. 2. Children who are willing to undergo blood tests for laboratory investigations

Exclusion criteria

Exclusion criteria: Tinea versicolor Chemical leucoderma Dermatological manifestation of leprosy Burn scar Pityriasis alba Total albinism White patches in mucous membrane

Design outcomes

Primary

Measure	Time frame
Reduction of the hypopigmented lesions over the affected areaTimepoint: 45 days	—

Secondary

Measure	Time frame
Reduction in the reccurence rate of the lesionsTimepoint: 3 months	—

Countries

India

Contacts

Public ContactK Shyamala

Government Siddha Medical College and Hospital,Palayamkottai.

shyamsujisathya@gmail.com9442277124

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026